Lab21 Investor Relations

Welcome to our Investor Relations pages. 

Lab21 is a dynamic and fast growing healthcare diagnostics company which specialises in providing patients, doctors, hospitals and healthcare providers with important high quality diagnostic information for disease identification, disease predisposition and personalised medicine, to help manage their health problems of today and tomorrow.

The company was founded with a view to building a major international diagnostics business through a buy and build strategy, coupled with organic growth of the core business products and services.

We take great pride from the fact that our work is directly impacting the health and outcome of people all around the world.  We believe that ‘prevention is better than cure’ and we aim to provide information that helps to protect people from the health problems of tomorrow.
If you cannot find the information you are looking for within these pages, please Contact Us with your enquiry.

News & Events

22.06.15
NOVACYT LAUNCHES MOLECULAR HPV SERVICE TO ITS NOVAPREP® CUSTOMERS
...
more >
01.06.15
NOVACYT AND LEICA BIOSYSTEMS LAUNCH NOVAPREP® IN CHINA
...
more >

Accreditation

Our commitment to quality

Find out more >

Email Alerts

Sign up for Lab21 email updates.

Register now >